Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: Insights from the ARTESiA trial

7 April 2024 (08:30 - 15:00)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Doctor William McIntyre

Population Health Research Institute, Hamilton (Canada)

9 More presentations in this session

Presentation thumbnail

Clinical benefits of the Closed Loop Stimulation in Sinus Node Disease

Doctor E. Pisano (Lecce, IT)

Presentation thumbnail

Clinical benefits of the Closed Loop Stimulation in Sinus Node Disease - discussion

Doctor N. Varma (Cleveland, US)

Presentation thumbnail

Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial.

Doctor J. Nikorowitsch (Hamburg, DE)

Presentation thumbnail

Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial. - discussion

Doctor S. Al-Khatib (Durham, US)

Presentation thumbnail

Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: Insights from the ARTESiA trial - discussion

Professor T. Potpara (Belgrade, RS)

Access the full session

Session thumbnail

Late-Breaking Science: devices

The Event

Event poster

EHRA 2024

7 April - 9 April 2024

You may be interested in

Congress Presentation

State-of-the-art lecture on stroke prevention in atrial fibrillation

Congress Presentation

Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro

Congress Session

Stroke prevention in clinical and subclinical atrial fibrillation

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources